Ligand Pharmaceuticals Acquires XOMA Royalty in a $739 Million Deal

Key Takeaways

• Ligand to pay $39 per XOMA share, 2.9% premium.
• Deal includes CVR tied to 75% of TREMFYA litigation proceeds.
• Acquisition funded by cash and existing credit facility.
• Transaction expected to close in Q3 2026.

Pulse Analysis

Ligand Pharmaceuticals and XOMA Royalty operate in a niche yet increasingly important segment of the biotech industry: royalty financing. By purchasing future payment streams from early‑stage drug candidates, both firms generate recurring revenue without bearing the full development risk. Ligand’s existing portfolio already includes royalties from several blockbuster therapies, and XOMA brings a diversified set of milestone and royalty interests, notably tied to candidates in oncology and immunology. The merger creates a larger, more resilient royalty engine that can attract additional capital and partnership opportunities.

The deal structure reflects Ligand’s confidence in XOMA’s pipeline and its pending litigation with Janssen Biotech over TREMFYA. Shareholders receive cash at a modest premium, while the contingent value right offers exposure to up to three‑quarters of any net proceeds from the lawsuit, aligning incentives for both parties. Funding the transaction through existing cash and a revolving credit facility minimizes dilution and preserves liquidity, a prudent move given the capital‑intensive nature of biotech royalty investments. The CVR also signals that Ligand anticipates a favorable outcome from the litigation, which could add a significant upside to the deal’s economics.

For investors, the acquisition underscores a broader trend of consolidation among royalty‑focused biopharma entities seeking scale and diversified risk. A larger royalty portfolio can smooth cash flow volatility, improve valuation multiples, and enhance bargaining power with pharmaceutical partners. As the industry continues to prioritize asset‑light models, Ligand’s expanded footprint positions it to capture a greater share of future drug revenues, potentially translating into higher dividend yields and stronger long‑term shareholder returns. The Q3 2026 closing timeline gives market participants a clear horizon to assess integration progress and the impact of the TREMFYA litigation on earnings forecasts.